Reirradiation for locoregionally recurrent non-small cell lung cancer

Melissa A.L. Vyfhuis, Stephanie Rice, Jill Remick, Sina Mossahebi, Shahed Badiyan, Pranshu Mohindra, Charles B. Simone

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Locoregional failure in non-small cell lung cancer (NSCLC) remains high, and the management for recurrent disease in the setting of prior radiotherapy is difficult. Retreatment options such as surgery or systemic therapy are typically limited or frequently result in suboptimal outcomes. Reirradiation (reRT) of thoracic malignancies may be an optimal strategy for providing definitive local control and offering a new chance of cure. Yet, retreatment with radiation therapy can be challenging for fear of excessive toxicities and the inability to safely deliver definitive (≥60 Gy) doses of reRT. However, with recent improvements in radiation delivery techniques and image-guidance, dose-escalation with reRT is possible and outcomes are encouraging. Here, we present a review of various radiation techniques, clinical outcomes and associated toxicities in patients with locoregionally recurrent NSCLC treated primarily with reRT.

Original languageEnglish
Pages (from-to)S2522-S2536
JournalJournal of Thoracic Disease
StatePublished - Aug 1 2018


  • Intensity modulated radiation therapy (IMRT)
  • Non-small cell lung cancer (NSCLC)
  • Proton beam therapy (PBT)
  • Reirradiation (reRT)
  • Stereotactic body radiation therapy (SBRT)


Dive into the research topics of 'Reirradiation for locoregionally recurrent non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this